AN2 THERAPEUTICS INC (ANTX) Stock Analyst Ratings
USA - NASDAQ:ANTX - US0373261058 - Common Stock
1.23 USD
-0.01 (-0.81%)
ChartMill assigns a Buy % Consensus number of 80% to ANTX. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 1.53. This target is 24.39% above the current price.
ANTX was analyzed by 8 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about ANTX.
In the previous month the buy percentage consensus was at a similar level.
ANTX was analyzed by 8 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-05-05 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-03-26 | Citizens Capital Markets | Reiterate | Market Outperform -> Market Outperform |
| 2025-02-25 | Citizens Capital Markets | Reiterate | Market Outperform -> Market Outperform |
| 2025-02-03 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-11-19 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-11-18 | TD Cowen | Downgrade | Buy -> Hold |
| 2024-08-09 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2024-07-03 | Leerink Partners | Upgrade | Market Perform -> Outperform |
| 2024-05-16 | Evercore ISI Group | Maintains | In-Line -> In-Line |
| 2024-04-02 | JMP Securities | Upgrade | Market Perform -> Market Outperform |
| 2024-04-01 | Oppenheimer | Reiterate | Perform -> Perform |
| 2024-02-13 | Leerink Partners | Downgrade | Outperform -> Market Perform |
| 2024-02-12 | JMP Securities | Downgrade | Market Outperform -> Market Perform |
| 2024-02-12 | Oppenheimer | Downgrade | Outperform -> Perform |
| 2024-02-12 | Evercore ISI Group | Downgrade | Outperform -> In-Line |
| 2024-01-04 | JMP Securities | Initiate | Market Outperform |
| 2023-03-30 | Oppenheimer | Maintains | Outperform |
| 2022-11-14 | SVB Leerink | Maintains | Outperform |
| 2022-04-19 | Oppenheimer | Initiate | Outperform |
| 2022-04-19 | Cowen & Co. | Initiate | Outperform |
| 2022-04-19 | Evercore ISI Group | Initiate | Outperform |
AN2 THERAPEUTICS INC / ANTX FAQ
What is the price target for ANTX stock?
8 analysts have analysed ANTX and the average price target is 1.53 USD. This implies a price increase of 24.39% is expected in the next year compared to the current price of 1.23.
How do analysts rate AN2 THERAPEUTICS INC (ANTX)?
The consensus rating for AN2 THERAPEUTICS INC (ANTX) is 80 / 100 . This indicates that analysts generally have a positive outlook on the stock.